Successful fibrin-rich plasma (frp) therapy and titanium plate for treating bone defect caused by bisphosphonates related osteonecrosis: a case report

Authors

DOI:

https://doi.org/10.29166/odontologia.vol21.n2.2019-123-135

Keywords:

Osteonecrosis of the jaw, bisphosphonate-associated osteonecrosis, zoledronic acid, fibrin-rich plasma

Abstract

Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a progressive condition that still has no consensus about its ideal treatment. Fibrin-rich plasma (FRP) therapy shows effectiveness on BRONJ’s treatment by clinicians. A 76-year-old male patient attended for our evaluation complaining of pain in his mouth for 8 months. The medical history showed multiple myeloma metastasis and the use of bisphosphonate (BP) for metastasis control. On intraoral clinical evaluation, suppuration and exposed bone was evident on posterior left mandible measuring approximately 4 centimeters. On panoramic radiograph, we observed a radiolucent image and an area of osseous trabeculae disorganization on left mandible. Computed Tomography (CT) image showed some destruction of lingual and buccal cortical, suggestive of bone sequestration. The treatment was to remove all necrotic bone and fill the defect with FRP from the patient's own blood. Sutures were placed to provide wound primary closure and after 2 months without evidence of exposed bone, the patient came complaining with pain again. After a panoramic radiograph, it was clearly observed a radiolucent image with an image of a jaw discontinuity line, suggestive of mandible fracture in the same side treated before. New surgery was performed and as the intraoral mucosa was perfectly healthy, an extraoral access was made. All the necrotic bone was removed and titanium plates were placed. After 3 months following up, there were signs of bone consolidation and no pain complaint by patient. The patient was able to eating properly and had his quality of life improved.

Downloads

Download data is not yet available.

Author Biographies

Ricardo Ramalho Vecchiatti

Specialization Coordinator Courses in Implantodontics at Unig - Iguaçu University and the Brazilian Association of Regional Dentistry Nova Iguaçu – Rio de Janeiro, Brazil (maxilofacial@globomail.com; Vecchiatti RR)

Thaís Gimenez Miniello

Stomatology Department, School of Dentistry, University of Sao Paulo, Sao Paulo, Brazil. (thaminiello@usp.br; Miniello TG)

References

Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–1575.

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61:1115.

Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72:1938–56.

Miniello TG, Araújo JP, Lopes RN, Alves FA. Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant. Braz Dent J. 2015 Jan-Feb;26(1):86-8. doi: 10.1590/0103-6440201300255.

Tong CK, Ho ST, Wong SL. Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis. Hong Kong Med J. 2010;16:145-8.

Miniello TG, Araújo JP, Silva MLG, Paulo Kowalski L, Rocha AC, Jaguar GC, Abreu Alves F. Influence of bisphosphonates on clinical features of osteoradionecrosis of the maxilla and mandible. Oral Dis. 2019 Jul;25(5):1344-1351. doi: 10.1111/odi.13081.

Schubert M, Klatte I, Linek W, Muller B, Doring K, Eckelt U, et al. The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 2012;48:349-54.

Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol. 2018;84:102-8.

Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-Related Osteonecrosis of the Jaw: The Use of Leukocyte-Platelet-Rich Fibrin as an Adjunct in the Treatment. J Craniofac Surg. 2019 Jun;30(4):1095-1101. doi: 10.1097/SCS.0000000000005475.

Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrina may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig. 2017 Sep;21(7):2165-2172. doi: 10.1007/s00784-016-2004-z.

Cano-Durán JA, Peña-Cardelles JF, Ortega-Concepción D, Paredes-Rodríguez VM, García-Riart M, López-Quiles J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J Clin Exp Dent. 2017 Aug 1;9(8):e1051-e1059. doi: 10.4317/jced.54154.

Badade PS, Mahale SA, Panjwani AA, Vaidya PD, Warang AD. Antimicrobial effect of platelet-rich plasma and platelet-rich fibrin. Indian J Dent Res. 2016 May-Jun;27(3):300-4. doi: 10.4103/0970-9290.186231.

Published

2019-07-01

How to Cite

Ramalho Vecchiatti, R., & Gimenez Miniello, T. (2019). Successful fibrin-rich plasma (frp) therapy and titanium plate for treating bone defect caused by bisphosphonates related osteonecrosis: a case report. Odontología, 21(2), 123–135. https://doi.org/10.29166/odontologia.vol21.n2.2019-123-135

Issue

Section

Case Report

Most read articles by the same author(s)